Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Los Angeles, California--(Newsfile Corp. - September 9, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medtronic plc ("Medtronic" or "the Company") (NYSE: MDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Medtronic plc with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $MDT #MDT--The Schall Law Firm Encourages Investors in Medtronic plc with Losses of $100,000 to Contact the Firm

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Medtronic plc with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than November 7, 2022. SO WHAT: If you purchased Medtronic securities during the Class Period you may be entitled to compensation without payment of

EQUITY ALERT: Rosen Law Firm Encourages Medtronic plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – MDT

Pinterest

RADNOR, Pa.--(BUSINESS WIRE)---- $PINS #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities fraud class action lawsuit in the United States District Court for the District of Minnesota against Medtronic plc (“Medtronic”) (NYSE: MDT) on behalf of all persons and entities who purchased or otherwise acquired Medtronic common stock between June 8, 2019, and May 25, 2022, inclusive (the “Class Period”). This action is captioned The Trust

Kessler Topaz Meltzer & Check, LLP Announces the Firm Has Filed a Securities Fraud Class Action Lawsuit Against Medtronic plc.

Medtronic (MDT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Most-Watched Stock Medtronic PLC (MDT) Worth Betting on Now?

DUBLIN , Sept. 7, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today confirmed its participation in the following September 2022 investor conferences: Wells Fargo 2022 Healthcare Conference Wednesday, September 7, 2022, at 11:35am EDT (10:35am CDT) Karen Parkhill, executive vice president & chief financial officer, IT & enterprise excellence answered questions about the company.

Medtronic to appear at September investor conferences

Medtronic plc (NYSE:MDT ) 2022 Wells Fargo Healthcare Conference Call September 7, 2022 11:35 AM ET Company Participants Karen Parkhill - Executive Vice President and Chief Financial Officer Gregory Hertz - Senior Director of Investor Relations Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities, LLC Lawrence Biegelsen All right. Good morning.

Medtronic plc (MDT) 2022 Wells Fargo Healthcare Conference Call Transcript

Is Medtronic a Buy?

Medtronic's dividend yield tops 3%, approximately double the S&P 500 index's yield.

Should Income Investors Buy This Dividend Aristocrat?

Medtronic's (MDT) new deal with BioIntelliSense will ensure accessibility to BioButton for continuous vital sign measurements of general care patients in the United States.

Medtronic (MDT) Obtains U.S. Distribution Rights for BioButton

First-of-its-kind study demonstrates individuals using the Medtronic system achieved 1.4% absolute reduction in A1c and 27.6% absolute increase in Time in Range DUBLIN , Sept. 1, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced results from the Medtronic ADAPT study were published in The Lancet Diabetes & Endocrinology.

Medtronic ADAPT study results published in The Lancet Diabetes & Endocrinology show improved glycemic control and treatment satisfaction among those using MiniMed™ 780G system¹, compared to insulin injections

Partnership reflects commitment to patient safety; BioButton® wearable offers up to 1,440 vital signs measurements daily, monitoring patients transitioning from higher to lower acuity settings Technology complements the Medtronic Patient Monitoring business' HealthCast™ intelligent patient manager portfolio designed for connectivity, visualization, remote patient monitoring, and now, wearables DUBLIN , Aug. 31, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a strategic partnership with BioIntelliSense, a continuous health monitoring and clinical intelligence company, for the exclusive U.S. hospital and 30-day post-acute hospital to home distribution rights of the BioButton® multi-parameter wearable for continuous, connected monitoring. The partnership enables the Medtronic Patient Monitoring business to offer access to a medical grade device that provides continuous vital sign measurements of general care patients in-hospital as well as post-discharge.

Medtronic announces partnership with BioIntelliSense for exclusive U.S. distribution of multi-parameter wearable for continuous remote patient monitoring from in-hospital to home

Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias DUBLIN , Aug. 30, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Affera, Inc. This acquisition expands the company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform that encompasses a differentiated, fully integrated diagnostic, focal pulsed field and radiofrequency ablation solution. The investigational Affera technology is designed to provide solutions for patients with cardiac arrhythmias (irregular heartbeats) such as atrial fibrillation (AF).

Medtronic completes acquisition of Affera

Individual and institutional investors, advisors, and analysts are invited to attend Cloud DX's interactive presentation at the Emerging Growth Conference Cloud DX and Teladoc Health announced a new partnership to deliver integrated remote patient monitoring (RPM) solutions to providers across Canada CEO Robert Kaul will present on the implications of the Agreement and update investors on other Cloud DX initiatives including the partnership with Medtronic KITCHENER, ON / ACCESSWIRE / August 30, 2022 / Cloud DX (TSXV:CDX)(OTCQB:CDXFF), is pleased to announce that it has been invited to present at the Emerging Growth Conference on August 31, 2022. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the company's Founder & CEO, Robert Kaul.

Cloud DX to Present on Teladoc Partnership and More at Emerging Growth Conference

Despite short-term headwinds, there are reasons for investors with a long-term outlook to consider Medtronic as a stock to manage through this recession.

Three Reasons Why Medtronic Stock can be a Recession Winner

Late-breaking data presented at ESC Congress 2022 and simultaneously published in The New England Journal of Medicine confirms implant procedure safety and defibrillation success DUBLIN and BARCELONA, Spain , Aug. 28, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its investigational EV ICD™ System – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial. Findings from the Extravascular Implantable Cardioverter Defibrillator (EV ICD) Pivotal Study were presented as late-breaking science today at the European Society of Cardiology (ESC) Congress 2022 in Barcelona and simultaneously published in The New England Journal of Medicine.

Medtronic Extravascular ICD meets global pivotal clinical trial's safety and effectiveness endpoints

Medtronic's revenue (Q1) of $7.4 billion was down 8%, while its EPS of $1.13 was down 17% y-o-y, compared to our estimates of $7.3 billion and $1.15, respectively.

Should You Buy Medtronic Stock Around $90?

Raymond James is losing confidence in the growth potential for Medtronic PLC (NYSE:MDT), according to a bear note the firm issued earlier today.

Analyst: Medtronic Stock's Future Growth is Doubtful

Raymond James on Wednesday cut its rating on medical products company Medtronic Plc MDT, -3.08% to market perform from outperform amid doubts about its implied revenue increases in the second half of fiscal 2023. Analyst Jayson Bedford said he's less confident in his performance estimates for the company.

Raymond James downgrades Medtronic to market perform on doubts around revenue growth

Medtronic plc (NYSE:MDT ) Q1 2023 Results Conference Call August 23, 2022 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Karen Parkhill - CFO Sean Salmon - EVP and President, Cardiovascular Portfolio Bob White - EVP and President, Medical Surgical Portfolio Brett Wall - EVP and President, Neuroscience Portfolio Que Dallara - EVP and President, Diabetes Operating Unit Conference Call Participants Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Travis Steed - Bank of America Global Research Cecilia Furlong - Morgan Stanley Larry Biegelsen - Wells Fargo Securities Joanne Wuensch - Citi Jayson Bedford - Raymond James Steve Lichtman - Oppenheimer & Co. Rich Newitter - Truist Securities Rick Wise - Stifel, Nicolaus & Company Ryan Weispfenning Good morning, and welcome to Medtronic's Fiscal Year 2023 First Quarter Earnings Broadcast. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations.

Medtronic plc (MDT) CEO Geoff Martha on Q1 2023 Results - Earnings Call Transcript

Medtronic (MDT) delivered earnings and revenue surprises of 0.89% and 2.34%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Q1 Earnings and Revenues Surpass Estimates

Medtronic beat fiscal first-quarter expectations Tuesday, but sales and adjusted profit both declined. MDT stock was flat, in response.

Medtronic Narrowly Beats Earnings Forecasts, Though Declines Continue

Medtronic Plc MDT, -2.01% said Tuesday its first-quarter net income increased by 22% to $929 million, or 70 cents a share, from $769 million, or 56 cents a share, in the year-ago quarter. Adjusted profit totaled $1.13 a share.

Medtronic earnings rise 22%, while revenue and adjusted profit beat estimates

Revenue exceeds guidance, with known supply chain challenges impacting results; notable strength in Pacing, Cardiac Surgery, Core Spine in the U.S., and Diabetes in Europe DUBLIN , Aug. 23, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2023, which ended July 29, 2022. Key Highlights GAAP diluted EPS of $0.70 increased 25%; non-GAAP diluted EPS of $1.13 decreased 17%, in-line with expectations Revenue of $7.4 billion decreased 8% as reported and 4% organic, ahead of expectations Company reiterates FY23 revenue and EPS guidance "We're executing in a challenging environment with several pipeline catalysts approaching.

Medtronic reports first quarter fiscal 2023 financial results

Medtronic, like many medical device makers, has seen poor share price action lately. I see considerable value with shares near the bottom of their 5-year trading range.

News for Medtronic Stock (MDT)